Hypercholesterolemia: Clinical Trials

122 trials for Hypercholesterolemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

122 completed. 122 Phase 2, 8 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2122Completed 122
Phase 18Completed 8
Phase 37Completed 7

Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia

Trials (filtered) newest first · largest first

All 122 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
SYH2053/placebo injection, Inclisiran (Leqvio®) 300mg - Hypercholesterolemia and Mixed Hyperlipidemia
Phase 2CompletedCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1562024-12-032026-02-19
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
RDX-002, Placebo - Triglycerides, Weight Gain Trajectory
Phase 2CompletedResponse Pharmaceuticals682024-09-272026-07-02
A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
SAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin - Hypercholesterolemia and Mixed Dyslipidemia
Phase 2CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.2142023-06-022025-12-12
Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)
HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia
Phase 2CompletedHaisco Pharmaceutical Group Co., Ltd.2102023-04-262024-04-09
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Bempedoic acid - Hypercholesterolemia
Phase 2CompletedEsperion Therapeutics, Inc.312023-01-122026-07-17
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia
Phase 2CompletedNewAmsterdam Pharma1022022-06-272024-10-29
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 2CompletedMerck Sharp & Dohme LLC3812022-03-102024-12-09
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol
Phase 2CompletedNewAmsterdam Pharma1192022-03-092024-07-03
Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia
Placebo, 250 mg OPP - Hyperlipidemias, Hypercholesterolemia
Phase 2CompletedIsa Naina Mohamed502021-10-182022-04-13
Supplements, Placebo, or Rosuvastatin Study
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo - Hypercholesterolemia
Phase 2CompletedThe Cleveland Clinic2032021-04-232023-05-25
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
180mg of ETC-1002(bempedoic acid), 120mg of ETC-1002(bempedoic acid), 60mg of ETC-1002(bempedoic acid) - Hypercholesterolemia
Phase 2CompletedOtsuka Pharmaceutical Co., Ltd.1882021-03-242024-05-10
Randomized Study of Obicetrapib in Combination With Ezetimibe
Obicetrapib 5mg, Ezetimibe 10mg, Placebo - Dyslipidemias, High Cholesterol
Phase 2CompletedNewAmsterdam Pharma1122021-02-232024-04-24
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Obicetrapib - Dyslipidemias, High Cholesterol
Phase 2CompletedNewAmsterdam Pharma1202021-02-182024-07-12
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Inclisiran sodium, Placebo - Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Phase 2CompletedNovartis Pharmaceuticals3122021-01-292024-06-20
Effects of Atorvastatin in Graves' Orbitopathy (GO)
Atorvastatin, Methylprednisolone - Thyroid Associated Ophthalmopathy, Hypercholesterolemia
Phase 2CompletedUniversity of Pisa882020-06-012021-08-13
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
AK102, Placebos, Statins and/or Ezetimibe - Hypercholesterolemia
Phase 2CompletedAkeso2622020-05-132023-03-02
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
CIVI 007 - Hypercholesterolemia
Phase 2CompletedCivi Biopharma, Inc.492019-11-112025-02-13
A Long-term Study of AK102 in Patients With Hypercholesterolemia
450mg AK102, 300mg AK102, 150mg AK102 - Hypercholesterolemia
Phase 2CompletedAkeso7962019-11-042023-03-02
Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
Alirocumab, Sham Control - ST Elevation Myocardial Infarction, Acute Coronary Syndrome
Phase 2CompletedPopulation Health Research Institute972019-03-112022-04-11
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
IBI306, placebo - Hypercholesterolemia
Phase 2CompletedInnovent Biologics (Suzhou) Co. Ltd.602019-03-072023-11-18

Showing 20 of 122. Sign in to see all of them.

Narrower conditions

Dyslipidemias (21)  ·  Hyperlipidemias (16)  ·  Cardiovascular Diseases (10)  ·  Hyperlipoproteinemia Type II (7)  ·  Hypertriglyceridemia (7)  ·  Atherosclerosis (6)  ·  Hypertension (6)  ·  Lipid Metabolism Disorders (6)  ·  Metabolic Diseases (5)  ·  Metabolic Syndrome (5)  ·  Coronary Disease (3)  ·  Homozygous Familial Hypercholesterolemia (3)  ·  Hypercholesterolemia, Autosomal Dominant, 3 (3)  ·  Obesity (3)

Broader conditions

Nutritional and Metabolic Diseases (121)  ·  Metabolic Diseases (117)  ·  Lipid Metabolism Disorders (116)  ·  Hyperlipidemias (106)  ·  Dyslipidemias (101)  ·  Vascular Diseases (14)  ·  Cardiovascular Diseases (11)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)  ·  Arterial Occlusive Diseases (7)  ·  Arteriosclerosis (7)  ·  Genetic Diseases, Inborn (7)  ·  Glucose Metabolism Disorders (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Endocrine System Diseases (6)  ·  Hyperlipoproteinemias (6)

Interventions

Atorvastatin (20)  ·  Ezetimibe (13)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (9)  ·  alirocumab (8)  ·  evolocumab (8)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (6)  ·  gemcabene (5)  ·  mipomersen (5)  ·  Pravastatin (4)  ·  Rosuvastatin Calcium (4)  ·  bococizumab (4)  ·  3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (3)  ·  BMS201038 (3)  ·  1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (2)  ·  Fenofibrate (2)

Sponsors

Esperion Therapeutics, Inc. (9)  ·  Amgen (7)  ·  Kastle Therapeutics, LLC (5)  ·  NeuroBo Pharmaceuticals Inc. (5)  ·  Sanofi (5)  ·  Micropharma Limited (4)  ·  National Heart, Lung, and Blood Institute (NHLBI) (4)  ·  NewAmsterdam Pharma (4)  ·  Pfizer (4)  ·  Regeneron Pharmaceuticals (4)  ·  Aegerion Pharmaceuticals, Inc. (3)  ·  Eli Lilly and Company (3)  ·  Karo Bio AB (3)  ·  Merck Sharp & Dohme LLC (3)  ·  National Center for Complementary and Integrative Health (NCCIH) (3)

Countries

United States (61)  ·  Canada (28)  ·  Netherlands (12)  ·  Japan (11)  ·  Australia (9)  ·  Czechia (8)  ·  Denmark (8)  ·  Spain (8)  ·  China (7)  ·  France (7)  ·  Sweden (7)  ·  Germany (6)  ·  United Kingdom (6)  ·  Belgium (5)  ·  Italy (5)

Top investigators

Ron Haberman, MD (2)  ·  Adrian Di Bisceglie, MD,FACP,FAASLD (1)  ·  Alison L Gibbs, PhD (1)  ·  Arshed A Quyyumi, MD (1)  ·  Barry Lubin, MD (1)  ·  Brad West, ND (1)  ·  Charles L Shear, DrPH (1)

Results publications

PMID 30183102, PMID 37994400, PMID 26872608, PMID 20707601, PMID 21518985, PMID 24014831, PMID 25060413, PMID 28181260, PMID 29037448, PMID 16996859, PMID 17030154, PMID 17298834, PMID 17325296, PMID 17384435, PMID 17392721, PMID 17434849, PMID 17556685, PMID 17987126, PMID 19364997, PMID 19500003, PMID 19506174, PMID 19810001, PMID 19843338, PMID 20008831, PMID 20220185, PMID 20378080, PMID 20428452, PMID 20527967, PMID 20660224, PMID 20668250, PMID 20875216, PMID 21593041, PMID 22089718, PMID 22118569, PMID 22264573, PMID 22301925, PMID 22463922, PMID 22484031, PMID 22507979, PMID 22561556, PMID 22633824, PMID 22698766, PMID 23113833, PMID 23148122, PMID 23174266, PMID 23221573, PMID 23262496, PMID 23840361, PMID 23884353, PMID 24074303

NIH funding

2005 (1), 2015 (1), 2017 (1), R01HL042554 (1), R01HL070742 (1), U01HL044315 (1)